Overview

Open Label Extension

Status:
Completed

Trial end date:
2006-10-27

Target enrollment:

Participant gender:

Summary

TRES will evaluate the effects of continued ALX1-11 treatment on the safety and efficacy variables assessed in the OLE study for a maximum treatment duration of 36 months in OLES and TRES combined.

Phase:

Phase 3

Details

Lead Sponsor:

Shire